Research programme: Streptococcus vaccine and antibody therapeutics - Valneva

Drug Profile

Research programme: Streptococcus vaccine and antibody therapeutics - Valneva

Alternative Names: Group A Streptococcus antibodies - Intercell; Group A Streptococcus antibodies - Valneva; Group A Streptococcus vaccine - Intercell; Group A Streptococcus vaccine - Valneva; Group B Streptococcus antibodies - Intercell; Group B Streptococcus antibodies - Valneva

Latest Information Update: 01 Jul 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intercell
  • Developer Valneva
  • Class Monoclonal antibodies; Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Streptococcal infections

Most Recent Events

  • 01 Jul 2013 No development reported - Preclinical for Streptococcal infections in Austria (Parenteral)
  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 01 Sep 2010 Preclinical development is ongoing with Intercell
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top